RNF169 and pancreatic adenocarcinoma: Thus, we evaluated the correlation between RNF169 and immune checkpoints and found that high expression of RNF169 was associated with CTLA4 or CD274, indicating that targeting RNF169 may be a potential approach to improve the efficacy of immunotherapy for PAAD.